Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Capital Expenditures (2016 - 2025)

Abeona Therapeutics has reported Capital Expenditures over the past 14 years, most recently at $7.7 million for Q4 2025.

  • Quarterly results put Capital Expenditures at $7.7 million for Q4 2025, up 236.58% from a year ago — trailing twelve months through Dec 2025 was $8.0 million (up 226.04% YoY), and the annual figure for FY2025 was $8.0 million, up 226.04%.
  • Capital Expenditures for Q4 2025 was $7.7 million at Abeona Therapeutics, up from -$1.1 million in the prior quarter.
  • Over the last five years, Capital Expenditures for ABEO hit a ceiling of $7.7 million in Q4 2025 and a floor of -$1.3 million in Q3 2024.
  • Median Capital Expenditures over the past 5 years was $103000.0 (2022), compared with a mean of $791210.5.
  • Biggest five-year swings in Capital Expenditures: soared 9742.42% in 2021 and later tumbled 2986.36% in 2024.
  • Abeona Therapeutics' Capital Expenditures stood at $3.2 million in 2021, then tumbled by 99.23% to $25000.0 in 2022, then skyrocketed by 48.0% to $37000.0 in 2023, then surged by 6062.16% to $2.3 million in 2024, then skyrocketed by 236.58% to $7.7 million in 2025.
  • The last three reported values for Capital Expenditures were $7.7 million (Q4 2025), -$1.1 million (Q3 2025), and -$37000.0 (Q2 2025) per Business Quant data.